Skip to main content
. 2013 Oct 29;2013:925702. doi: 10.1155/2013/925702

Table 5.

Clinical trials characteristics and results of the association of donepezil plus memantine in moderate-severe AD.

First author and no. in the list of references Severity Mean age years Mean MMSE at baseline Duration of the study N Test
Howard et al. 2012 [29] MMSE 5–13 77.1 ± 8 9.1 ± 2.6 52 weeks 295 MMSE
BADLS
NPI
PROXY

Doody et al. 2012 [30] MMSE 0–20 Memantine: 73.6 (8.63) 
Placebo: 74.0 (8.48)
13.8 (4.63) 24 weeks 1436 MMSE
CIBIC-plus
ACDS-ADL-sev
SIB